

a. 論文

- (1) 四柳宏, 塚田訓久, 三田英治, 遠藤知之, 湯永博之, 木村哲; HIV/HCV 重複感染者に対するソホスブビルの使用成績. 日本エイズ学会誌 (投稿中)
- (2) Miura S, Hidaka M, Takatsuki M, Natsuda K, Soyama A, Miyaaki H, Kanda Y, Tamada Y, Shibata H, Ozawa E, Taura N, Eguchi S, Nakao K; Current characteristics of hemophilia patients co-infected with HIV/HCV in Japan. *Exp Ther Med* 15: 2148-2155, 2018
- (3) Ogishi M, Yotsuyanagi H; Prediction of HIV-associated neurocognitive disorder (HAND) from three genetic features of envelope gp120 glycoprotein. *Retrovirology* 27; 15(1): 12 doi: 10.1186/s12977-018-0401-x, 2018
- (4) Murata K, Asano M, Matsumoto A, Sugiyama M, Nishida N, Tanaka E, Inoue T, Sakamoto M, Enomoto N, Shirasaka T, Honda M, Kaneko S, Gatanaga H, Oka S, Kawamura YI, Dohi T, Shuno Y, Yano H, Mizokami M; Identification of IFN- λ 3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. *Gut* 67: 362-371, 2018
- (5) Tsuchiya K, Ohuchi M, Yamane N, Aikawa H, Gatanaga H, Oka S, Hamada A; High-performance liquid chromatography-tandem mass spectrometry for simultaneous determination of raltegravir, dolutegravir and elvitegravir concentrations in human plasma and cerebrospinal fluid samples. *Biomedical Chromatography* 32: e4058, 2018
- (6) Tsuboi M, Nishijima T, Yashiro S, Teruya K, Kikuchi Y, Katai N, Gatanaga H, Oka S; Time to development of ocular syphilis after syphilis infection. *Journal of infection and chemotherapy* 24: 75-77, 2018
- (7) Nishijima T, Mutoh Y, Lawasaki Y, Tomonari K, Kikuchi Y, Gatanaga H, Oka S, ACC Study Team; Cumulative exposure of tenofovir disoproxil fumarate is associated with kidney tubulopathy whether it is currently used or discontinued in HIV-infected patients. *AIDS* 32: 179-188, 2018
- (8) Miyaaki H, Takatsuki M, Ichikawa T, Hidaka M, Soyama A, Ohdan H, Inomata Y, Uemoto S, Kokudo N, Nakao K, Eguchi S; Intrahepatic microRNA profile of liver transplant recipients with hepatitis C virus co-infected with human immunodeficiency virus. *Ann Transplant* 22: 701-706, 2017
- (9) Natsuda K, Takatsuki M, Tanaka T, Soyama A, Adachi T, Ono S, Hara T, Baimakhanov Z, Imamura H, Okada S, Hidaka M, Eguchi S; Aspartate transaminase-platelet ratio and Fibrosis-4 indices as effective markers for monitoring esophageal varices in HIV/hepatitis C virus co-infected patients due to contaminated blood products for hemophilia. *Hepatology Research* 47: 1282-1288, 2017
- (10) Yamada N, Sugiyama R, Nitta S, Murayama A, Kobayashi M, Okuse C, Suzuki M, Yasuda K, Yotsuyanagi H, Moriya K, Koike K, Wakita T, Kato T; Resistance mutations of hepatitis B virus in entecavir-refractory patients. *Hepatology Commun* 1: 110-121, 2017
- (11) Kato M, Hamada-Tsutsumi S, Okuse C, Sakai A, Matsumoto N, Sato M, Sato T, Arito M, Omoteyama K, Suematsu N, Okamoto K, Kato T, Itoh F, Sumazaki R, Tanaka Y, Yotsuyanagi H, Kato T, Kurokawa MS; Effects of vaccine-acquired polyclonal anti-HBs antibodies on the prevention of HBV infection of non-vaccine genotypes. *J Gastroenterol* doi: 10.1007/s00535-017-1316-3, 2017
- (12) Tsutsumi T, Okushin K, Enooku K, Fujinaga H, Moriya K, Yotsuyanagi H, Aizaki H, Suzuki T, Matsuura Y, Koike K; Nonstructural 5A protein of hepatitis c virus interferes with Toll-like receptor signaling and suppresses the interferon response in mouse liver. *PLoS One* 20; 12(1): e0170461 doi: 10.1371/journal.pone.0170461 eCollection 2017
- (13) Ikeda H, Watanabe T, Okuse C, Matsumoto N, Ishii T, Yamada N, Shigefuku R, Hattori N, Matsunaga K, Nakano H, Hiraishi T, Kobayashi M, Yasuda K, Yamamoto H, Yasuda H, Kurosaki M, Izumi N, Yotsuyanagi H, Suzuki M, Itoh F; Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir. *J Med Virol* 89, 99-105, 2017
- (14) Kawado M, Hashimoto S, Oka S, Fukutake K, Higasa S, Yatsuhashi H, Ogane M, Okamoto M, Shirasaka T; Clinical improvement by switching to an integrase strand transfer inhibitor in hemophilic patients with HIV: The Japan cohort study of HIV patients infected through blood products. *The Open AIDS Journal* 11, 2017
- (15) Kamori D, Hasan Z, Ohashi J, Kawana-Tachikawa A, Gatanaga H, Oka S, Ueno T; Identification of two unique naturally occurring Vpr sequence polymorphisms associated with clinical parameters in HIV-1 chronic infection. *Journal of Medical Virology* 89: 123-129, 2017
- (16) Kobayashi T, Watanabe K, Yano H, Murata Y, Igari T, Nakada-Tsukui K, Yagita K, Nozaki T, Kaku M, Tsukada K, Gatanaga H, Kikuchi Y, Oka S; Underestimated amoebic appendicitis among HIV-1-infected individuals in Japan.

Journal of Clinical Microbiology 55: 313-320, 2017

- (17) Murakoshi H, Koyanagi M, Chikata T, Rahman MA, Kuse N, Sakai K, Gatanaga H, Oka S, Takiguchi M; Accumulation of Pol mutations selected by HLA-B*52:01-C*12:02 protective haplotype-restricted CTLs causes low plasma viral load due to low viral fitness of mutant viruses. Journal of Virology 91: e02082-16, 2017
- (18) Kinai E, Gatanaga H, Mizushima D, Nishijima T, Aoki T, Genka I, Teruya K, Tsukada K, Kikuchi Y, Oka S; Protease inhibitor-associated bone mineral density loss is related to hypothyroidism and related bone turnover acceleration. Journal of Infection and Chemotherapy 23 : 259-264, 2017
- (19) Suzuki S, Nishijima T, Kawasaki Y, Kurosawa T, Mutoh Y, Kikuchi Y, Gatanaga H, Oka S; Effect of tenofovir disoproxil fumarate on incidence of chronic kidney disease and rate of estimated glomerular filtration rate decrement in HIV-1-infected treatment-naïve Asian patients: results from 12-year observational cohort. AIDS Patient Care and STDs 31: 105-112, 2017
- (20) Hayashida T, Tsuchiya K, Kikuchi Y, Oka S, Gatanaga H*; Emergence of CXCR4-tropic HIV-1 variants followed by rapid disease progression in hemophilic slow progressors. PLoS One 12 : e0177033, 2017
- (21) Hirakawa H, Gatanaga H, Ochi H, Fukuda T, Sunamura S, Oka S, Takeda S, Sato S; Antiretroviral therapy containing HIV protease inhibitors enhances fracture risk by impairing osteoblast differentiation and bone quality. Journal of Infectious Diseases 215: 1893-1897, 2017
- (22) Goto N, Takahashi-Nakazato A, Futamura K, Okada M, Yamamoto T, Tsujita M, Hiramitsu T, Narumi S, Tsuchiya K, Gatanaga H, Watarai Y, Oka S; Lifelong prophylaxis with trimethoprim-sulfamethoxazole for prevention of outbreak of Pneumocystis jirovecii pneumonia in kidney transplant recipients. Transplantation Direct 3: e151, 2017
- (23) Gatanaga H*, Brumme ZL, Adland E, Reyes-Teran G, Avila-Rios S, Mejia-Villatoro CR, Hayashida T, Chikata T, Van Tran G, Van Nguyen K, Meza RI, Palou EY, Valenzuela-Ponce H, Pascale JM, Porras-Cortes G, Manzanero M, Lee GQ, Martin JN, Carrington MN, John M, Mallal S, Poon AFY, Goulder P, Takiguchi M, Oka S, International HIV Adaptation Collaborative; Potential for immune-driven viral polymorphisms to compromise antiretroviral-based preexposure prophylaxis for prevention of HIV-1 infection. AIDS 31: 1935-1943, 2017
- (24) Tsuchiya K, Hayashida T, Hamada A, Oki S, Oka S, Gatanaga H*; High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants. Pharmacogenetics and Genomics 27: 416-419, 2017
- (25) Okahara K, Nagata N, Shimada T, Joya A, Hayashida T, Gatanaga H, Oka S, Sakurai T, Uemura N, Akiyama J; Colonic cytomegalovirus detection by mucosal PCR and antiviral therapy in ulcerative colitis. PLoS One 12: e0183951, 2017
- (26) Shimada T, Nagata N, Okahara K, Joya A, Hayashida T, Oka S, Sakurai T, Akiyama J, Uemura N, Gatanaga H; PCR detection of human herpesviruses in colonic mucosa of individuals with inflammatory bowel disease: comparison with individuals with immunocompetency and HIV infection. PLoS One 12: e0184699, 2017
- (27) Chikata T, Murakoshi H, Koyanagi M, Honda K, Gatanaga H, Oka S, Takiguchi M; Control of HIV-1 by an HLA-B*52:01-C*12:02 protective haplotype. Journal of Infectious Diseases 216: 1415-1424, 2017
- (28) Uemura H, Tsukada K, Mizushima D, Aoki T, Watanabe K, Kinai E, Teruya K, Gatanaga H, Kikuchi Y, Sugiyama M, Mizokami M, Oka S; Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders. PLoS One 12: e0186255, 2017
- (29) Matono T, Nishijima T, Teruya K, Morino E, Takasaki J, Gatanaga H, Kikuchi Y, Kaku M, Oka S; Substantially higher and earlier occurrence of anti-tuberculosis drug-related adverse reactions in HIV coinfecting tuberculosis patients: a matched-cohort study. AIDS Patient Care and STDs 31: 455-462, 2017
- (30) Nishijima T, Kawasaki Y, Mutoh Y, Tomonari K, Tsukada K, Kikuchi Y, Gatanaga H, Oka S; Prevalence and factors associated with chronic kidney disease and end-stage renal disease in HIV-1-infected Asian patients in Tokyo. Scientific Reports 7: 14565, 2017
- (31) 薩田祐輔, 平石哲也, 奥瀬千晃, 鈴木達也, 森田望, 末谷敬吾, 中野弘康, 石郷岡晋也, 石井俊哉, 高橋秀明, 池田裕喜, 渡邊綱正, 松永光太郎, 松本伸行, 四柳宏, 伊東文生, 鈴木通博; アメーバ性大腸炎に続発した B 型急性肝炎の 1 例. 肝臓 58: 626-631, 2017
- (32) 杉野祐子, 島田恵, 池田和子, 大金美和; HIV 感染症 / AIDS 患者用知識尺度の作成と信頼・妥当性の検証. 日本慢性看護学会誌 11(1), 2017
- (33) Wada K, Yoshikawa T, Lee J. J., Mitsuda T, Kidouchi K, Kurosawa H, Morisawa Y, Aminaka M, Okubo T, Kimura S, Moriya K; Sharp injuries in Japanese operating theaters of HIV/AIDS referral hospitals 2009-2011. Industrial Health 54: 224-229, 2016

- (34) 木村哲 ; 全国保健所等における HIV 抗体検査件数と新規 HIV 感染者報告数の関連 . 日本エイズ学会誌 18(1): 79-85, 2016
- (35) 木村哲 ; HIV 感染症の最近の動向ー世界と日本の疫学状況、抗 HIV 療法 (ART) の進歩等ー . 感染制御 11(3): 223-229, 2016
- (36) 木村哲 ; HIV 感染症について . 感染と消毒 23(2): 86-92, 2016
- (37) 木村哲 (監訳); 成人および青少年 HIV-1 感染者における抗レトロウイルス薬の使用に関するガイドライン 2016 年 7 月 14 日版 . テクノミック , 東京 , 2016
- (38) Imanaka K, Ohkawa K, Tatsumi T, Katayama K, Inoue A, Imai Y, Oshita M, Iio S, Mita E, Fukui H, Yamada A, Hijioka T, Inada M, Doi Y, Suzuki K, Kaneko A, Marubashi S, Fukui YI, Sakamori R, Yakushijin T, Hiramatsu N, Hayashi N, Takehara T, Forum OL; Impact of branched-chain amino acid supplementation on the survival in patients with advanced hepatocellular carcinoma treated with sorafenib; a multicenter retrospective cohort study. *Hepatol Res* 46(10): 1002-10, 2016
- (39) Okanou T, Shima T, Hasebe C, Karino Y, Imazeki F, Kumada T, Minami M, Imai Y, Yoshihara H, Mita E, Morikawa T, Nishiguchi S, Kawakami Y, Nomura H, Sakisaka S, Kurosaki M, Yatsushashi H, Oketani M, Kohno H, Masumoto A, Ikeda K, Kumada H ; Long-term follow-up of peginterferon- α -2a treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B patients in phase II and III studies. *Hepatol Res* 46(10): 992-1001, 2016
- (40) Tahata Y, Hiramatsu N, Oze T, Urabe A, Morishita N, Yamada R, Yakushijin T, Hosui A, Oshita M, Kaneko A, Hagiwara H, Mita E, Ito T, Yamada Y, Inada M, Katayama K, Tamura S, Imai Y, Hikita H, Sakamori R, Yoshida Y, Tatsumi T, Hayashi N, Takehara T; Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy. *J Med Virol* 88(10): 1776-84, 2016
- (41) Nishida N, Ohashi J, Khor SS, Sugiyama M, Tsuchiura T, Sawai H, Hino K, Honda M, Kaneko S, Yatsushashi H, Yokosuka O, Koike K, Kurosaki M, Izumi N, Korenaga M, Kang JH, Tanaka E, Taketomi A, Eguchi Y, Sakamoto N, Yamamoto K, Tamori A, Sakaida I, Hige S, Itoh Y, Mochida S, Mita E, Takikawa Y, Ide T, Hiasa Y, Kojima H, Yamamoto K, Nakamura M, Saji H, Sasazuki T, Kanto T, Tokunaga K, Mizokami M; Understanding of HLA-conferred susceptibility to chronic hepatitis B infection requires HLA genotyping-based association analysis. *Sci Rep* 6: 24767, 2016
- (42) Ikeda H, Watanabe T, Okuse C, Matsumoto N, Ishii T, Yamada N, Shigefuku R, Hattori N, Matsunaga K, Nakano H, Hiraishi T, Kobayashi M, Yasuda K, Yamamoto H, Yasuda H, Kurosaki M, Izumi N, Yotsuyanagi H, Suzuki M, Itoh F; Impact of resistance-associated variant dominance on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir. *J Med Virol* 89: 99-105, 2017
- (43) Okushin K, Tsutsumi T, Enooku K, Fujinaga H, Kado A, Shibahara J, Fukayama M, Moriya K, Yotsuyanagi H, Koike K; The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease. *J Gastroenterol* 51: 808-18, 2016
- (44) Ogishi M, Yotsuyanagi H, Moriya K, Koike K; Delineation of autoantibody repertoire through differential proteogenomics in hepatitis C virus-induced cryoglobulinemia. *Sci Rep* 6: 29532. doi: 10.1038/srep29532, 2016
- (45) Ikeda H, Okuse C, Watanabe T, Matsumoto N, Matsunaga K, Shigefuku R, Hattori N, Hiraishi T, Fukuda Y, Noguchi Y, Ishii T, Shima J, Nakahara K, Yamamoto H, Yasuda H, Yotsuyanagi H, Koike K, Itoh F, Suzuki M; Can the Abbott Real Time hepatitis C virus assay be used to predict therapeutic outcomes in hepatitis C virus-infected patients undergoing triple therapy? *Turk J Gastroenterol* 27: 165-72, 2016
- (46) Asahina Y, Izumi N, Hiromitsu K, Kurosaki M, Koike K, Suzuki F, Takikawa H, Tanaka A, Tanaka E, Tanaka Y, Tsubouchi H, Hayashi N, Hiramatsu N, Yotsuyanagi H; JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2. *Hepatol Res* 46: 129-65, 2016
- (47) Matsumoto C, Akiyama T, Maruta T, Higuchi S, Nakane H, Ohta J, Kanba S; ICD-11 beta draft survey in Japan. *Psychiatry Clin Neurosci* 70: 422-423, 2016
- (48) 森藤香奈子, 大石和代, 花田裕子, 山本直子, 折田真紀子, 徳永瑛子, 岩永竜一郎, 吉田浩二, 井口茂, 浦田秀子, 大津留晶, 矢部博興, 松坂誠應, 田中悟郎, 中根秀之; 福島県川内村における子育て世代の抱える多重ストレスに関する質的研究 . 長崎医学会雑誌 91(特集号別冊) : 230-233, 2016
- (49) 徳永瑛子, 岩永竜一郎, 大石和代, 花田裕子, 森藤香奈子, 山本直子, 折田真紀子, 吉田浩二, 井口茂, 浦田秀子, 前田正治, 大津留晶, 矢部博興, 松坂誠應, 田中悟郎, 中根秀之; 東日本大震災の子どもたちへの影響~子どもの強さと困難さ尺度 (SDQ) を用いて~ . 長崎医学会雑誌 91(特集号別冊) : 227-229, 2016
- (50) Miyazaki N, Sugiura W, Gatanaga H, Watanabe D, Yamamoto Y, Yokomaku Y, Yoshimura K, Matsushita S;

- Japanese HIV-MDR Study Group; High antiretroviral coverage and viral suppression prevalence in Japan: an excellent profile for downstream HIV care spectrum. *Japanese Journal of Infectious Diseases* (in press)
- (51) Lin Z, Kuroki K, Kuse N, Sun X, Akahoshi T, Qi Y, Chikata T, Naruto T, Koyanagi M, Murakoshi H, Gatanaga H, Oka S, Carrington M, Maenaka K, Takiguchi M; HIV-1 control by NK cells via reduced interaction between KIR2DL2 and HLA-C*12:02/C*14:03. *Cell Reports* 17:2210-2220, 2016
- (52) Kamori D, Hasan Z, Ohashi J, Kawana-Tachikawa A, Gatanaga H, Oka S, Ueno T; Identification of two unique naturally occurring Vpr sequence polymorphisms associated with clinical parameters in HIV-1 chronic infection. *Journal of Medical Virology* 89: 123-129, 2017
- (53) Boonchawalit S, Harada S, Shirai N, Gatanaga H, Oka S, Matsushita S, Yoshimura K; Impact of maraviroc-resistant mutation M434I in the C4 region of HIV-1 gp120 on sensitivity to antibody-mediated neutralization. *Japanese Journal of Infectious Diseases* 69: 236-243, 2016
- (54) Hattori J, Shiino T, Gatanaga H, Mori H, Minami R, Uchida K, Sadamasu K, Kondo M, Sugiura W, Japanese Drug Resistance HIV-1 Surveillance Network; Characteristics of transmitted drug-resistant HIV-1 in recently infected treatment-naïve patients in Japan. *Journal of Acquired Immune Deficiency Syndrome* 71: 367-373, 2016
- (55) Hosaka M, Fujisaki S, Masakane A, Hattori J, Shiino T, Gatanaga H, Shigemi U, Okazaki R, Hachiya A, Matsuda M, Ibe S, Iwatani Y, Yokomaku Y, Sugiura W, Japanese Drug Resistance HIV-1 Surveillance Network; HIV-1 CRF01_AE and subtype B transmission networks crossover: a new AE/B recombinant identified in Japan. *AIDS Research and Human Retroviruses* 32: 412-419, 2016
- (56) Ondondo B, Murakoshi H, Clutton G, Abdul-Jawad S, Wee EG, Gatanaga H, Oka S, McMichael AJ, Takiguchi M, Korber B, Hanke T; Novel conserved-region T-cell mosaic vaccine with high global HIV-1 coverage is recognized by protective responses in untreated infection. *Molecular Therapy* 24 : 832-842, 2016
- (57) Kinai E, Kato S, Hosokawa S, Sadatsuki M, Gatanaga H, Kikuchi Y, Lam NV, Ha DQ, Kinh NV, Liem NT, Oka S; High plasma concentrations of zidovudine (AZT) do not parallel intracellular concentrations of AZT-triphosphates in infants during prevention of mother-to-child HIV-1 transmission. *Journal of Acquired Immune Deficiency Syndrome* 72: 246-253, 2016
- (58) Nishijima T, Kurosawa T, Tanaka N, Kawasaki Y, Kikuchi Y, Oka S, Gatanaga H; Urinary β -2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy. *AIDS* 30 : 1563-1571, 2016
- (59) Kobayashi T, Nishijima T, Teruya K, Aoki T, Kikuchi Y, Oka S, Gatanaga H; High mortality of disseminated non-tuberculous mycobacterial infection in HIV-infected patients in the antiretroviral therapy era. *PLoS One* 11: e0151682, 2016
- (60) Tsuboi M, Nishijima T, Yashiro S, Teruya K, Kikuchi Y, Katai N, Oka S, Gatanaga H; Prognosis of ocular syphilis in patients infected with HIV in the antiretroviral therapy era. *Sexually Transmitted Infections* 92: 605-610, 2016
- (61) Tsuchiya K, Hayashida T, Hamada A, Oka S, Gatanaga H; High peak level of plasma raltegravir concentration in patients with ABCB1 and ABCG2 genetic variants. *Journal of Acquired Immune Deficiency Syndrome* 72: 11-14, 2016
- (62) Sun X, Shi Y, Akahoshi T, Fujiwara M, Gatanaga H, Schonbach C, Kuse N, Appay V, Gao GF, Oka S, Takiguchi M; Effects of a single escape mutation on T cell and HIV-1 co-adaptation. *Cell Reports* 15: 2279-2291, 2016
- (63) Yanagawa Y, Nagata N, Watanabe K, Tsukada K, Teruya K, Kikuchi Y, Gatanaga H, Akiyama J, Uemura N, Oka S; Increases in *Entamoeba histolytica* antibody-positive rates in human immunodeficiency virus-infected and noninfected patients in Japan: a 10-year hospital-based study of 3,514 patients. *American Journal of Tropical Medicine and Hygiene* 95: 604-609, 2016
- (64) Hayashida T, Hachiya A, Ode H, Nishijima T, Tsuchiya K, Sugiura W, Takiguchi M, Oka S, Gatanaga H; Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations. *Journal of Antimicrobial Chemotherapy* 71: 2760-2766, 2016
- (65) Tsuboi M, Nishijima T, Teruya K, Kikuchi Y, Gatanaga H, Oka S; Cerebral syphilitic gumma within 5 months of syphilis in HIV-infected patient. *Emerging Infectious Diseases* 22: 1846-1848, 2016
- (66) Nishijima T, Teruya K, Shibata S, Yanagawa Y, Kobayashi T, Mizushima D, Aoki T, Kinai E, Yazaki H, Tsukada K, Genka I, Kikuchi Y, Oka S, Gatanaga H; Incidence and risk factors for incident syphilis among HIV-1-infected men who have sex with men in a large urban HIV clinic in Tokyo 2008-2015. *PLoS One* 11: e0168642, 2016
- (67) 木村哲 ; 全国保健所等における HIV 抗体検査件数と新規 HIV 感染者報告数の関連 . 日本エイズ学会誌

18(1): 79-85, 2016

- (68) Ogishi M, Yotsuyanagi H, Tsutsumi T, Gatanaga H, Ode H, Sugiura W, Moriya K, Oka S, Kimura S, Koike K; Deconvoluting the composition of low-frequency hepatitis C viral quasispecies: Comparison of genotypes and NS3 resistance-associated variants between HCV/HIV coinfecting hemophiliacs and HCV monoinfected patients in Japan. *PLoS ONE* 10(3): e0119145. doi: 10.1371/journal.pone.0119145, 2015
- (69) 久地井寿哉, 柿沼章子, 岩野友里, 藤谷順子, 大金美和, 大平勝美, 木村哲; ICF (国際生活機能分類) コアセット 7 項目版尺度の信頼性と因子妥当性の検証－血液凝固因子製剤による HIV 感染被害者を対象とした分析－. *日本エイズ学会誌* 17(2): 90-96, 2015
- (70) Natsuda K, Eguchi S, Takatsuki M, Soyama A, Hidaka M, Hara T, Kugiyama T, Baimakhanov Z, Ono S, Kitasato A, Fujita F, Kanetaka K, Kuroki T; CD4 T lymphocyte counts in patients undergoing splenectomy during living donor liver transplantation. *Transpl Immunol* 34: 50-53, 2016
- (71) Eguchi S, Takatsuki M, Soyama A, Hidaka M, Kugiyama T, Natsuda K, Adachi T, Kitasato A, Fujita F, Kuroki T; The first case of deceased donor liver transplantation for a patient with end-stage liver cirrhosis due to human immunodeficiency virus and hepatitis C virus coinfection in Japan. *Jpn J Infect Dis* 69: 80-82, 2016
- (72) 江口晋; 血液製剤による HIV/HCV 重複感染者に対する肝移植－最近わかった諸々のこと－. *Frontiers in Gastroenterology* 20(1): 20-27, 2015
- (73) Imanaka K, Ohkawa K, Tatsumi T, Katayama K, Inoue A, Imai Y, Oshita M, Iio S, Mita E, Fukui H, Yamada A, Hijioka T, Inada M, Doi Y, Suzuki K, Kaneko A, Marubashi S, Fukui YI, Sakamori R, Yakushijin T, Hiramatsu N, Hayashi N, Takehara T, the Osaka Liver Forum; Impact of branched-chain amino acid supplementation on the survival in patients with advanced hepatocellular carcinoma treated with sorafenib; A multicenter retrospective cohort study. *Hepatol Res* doi: 10.1111/hepr.12640, 2016
- (74) Yoshio S, Sugiyama M, Shoji H, Mano Y, Mita E, Okamoto T, Matsuura Y, Okuno A, Takikawa O, Mizokami M, Kanto T; Indoleamine-2,3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B. *Hepatology* 63(1): 83-94, 2016
- (75) Okanoue T, Shima T, Hasebe C, Karino Y, Imazeki F, Kumada T, Minami M, Imai Y, Yoshihara H, Mita E, Morikawa T, Nishiguchi S, Kawakami Y, Nomura H, Sakisaka S, Kurosaki M, Yatsushashi H, Oketani M, Kohno H, Masumoto A, Ikeda K, Kumada H; Long-term follow up of peginterferon- α -2a treatment of hepatitis B e-antigen (HBeAg) positive and HBeAg negative chronic hepatitis B patients in phase II and III studies. *Hepatol Res* doi: 10.1111/hepr.12638, 2016
- (76) Ito K, Yotsuyanagi H, Sugiyama M, Yatsushashi H, Karino Y, Takikawa Y, Saito T, Arase Y, Imazeki F, Kurosaki M, Umemura T, Ichida T, Toyoda H, Yoneda M, Tanaka Y, Mita E, Yamamoto K, Michitaka K, Maeshiro T, Tanuma J, Korenaga M, Murata K, Masaki N, Koike K, Mizokami M, The Japanese AHB CHB Study Group; Geographic distribution and characteristics of genotype A hepatitis B virus infection in acute and chronic hepatitis B patients in Japan. *J Gastroenterol Hepatol* 31: 180-189, doi: 10.1111/jgh.13030, 2016
- (77) Tahata Y, Hiramatsu N, Oze T, Morishita N, Harada N, Yamada R, Yakushijin T, Mita E, Hagiwara H, Yamada Y, Ito T, Hijioka T, Inada M, Katayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Irishio K, Kato M, Hikita H, Sakamori R, Miyagi T, Yoshida Y, Tatsumi T, Hamasaki T, Hayashi N, Takehara T; The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin. *J Gastroenterol* doi: 10.1007/s00535-015-1105-9, 2015
- (78) Migita K, Jiuchi Y, Furukawa H, Nakamura M, Komori A, Yasunami M, Kozuru H, Abiru S, Yamasaki K, Nagaoka S, Hashimoto S, Bekki S, Yoshizawa K, Shimada M, Kouno H, Kamitsukasa H, Komatsu T, Hijioka T, Nakamuta M, Naganuma A, Yamashita H, Nishimura H, Ohta H, Nakamura Y, Ario K, Oohara Y, Sugi K, Tomizawa M, Sato T, Takahashi H, Muro T, Makita F, Mita E, Sakai H, Yatsushashi H; Lack of association between the CARD10 rs6000782 polymorphism and type 1 autoimmune hepatitis in a Japanese population. *BMC Research Notes* 8: 777, doi: 10.1186/s13104-015-1733-4, 2015
- (79) Migita K, Komori A, Kozuru H, Jiuchi Y, Nakamura M, Yasunami M, Furukawa H, Abiru S, Yamasaki K, Nagaoka S, Hashimoto S, Bekki S, Kamitsukasa H, Nakamura Y, Ohta H, Shimada M, Takahashi H, Mita E, Hijioka T, Yamashita H, Kouno H, Nakamuta M, Ario K, Muro T, Sakai H, Sugi K, Nishimura H, Yoshizawa K, Sato T, Naganuma A, Komatsu T, Oohara Y, Makita F, Tomizawa M, Yatsushashi H; Circulating microRNA profiles in patients with type-1 autoimmune hepatitis. *PLoS ONE* 10(11):e0136908, doi: 10.1371/journal.pone.0136908, 2015
- (80) Yamada R, Hiramatsu N, Oze T, Morishita N, Harada N, Yakushijin T, Iio S, Doi Y, Yamada A, Kaneko A,

- Hagiwara H, Mita E, Oshita M, Itoh T, Fukui H, Hijioka T, Katayama K, Tamura S, Yoshihara H, Imai Y, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hamasaki T, Hayashi N, Takehara T, Osaka Liver Forum; Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection. *J Gastroenterol* 50:785-794, doi: 10.1007/s100535-014-1010-7, 2015
- (81) Oze T, Hiramatsu N, Yakushijin T, Yamada R, Harada N, Morishita N, Oshita M, Mita E, Ito T, Inui Y, Inada M, Tamura S, Yoshihara H, Imai Y, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hayashi N, Takehara T; The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1. *J Viral Hepat* 22:254-262, doi: 10.1111/jvh.12289, 2015
- (82) Sakakibara Y, Nakazuru S, Yamada T, Iwasaki T, Iwasaki R, Ishihara A, Nishio K, Ishida H, Kodama Y, Mita E; Anaplastic lymphoma kinase-negative anaplastic large cell lymphoma with colon involvement. *Can J Gastroenterol Hepatol* 29(7):345-346, 2015
- (83) Kanehara A, Umeda M, Kawakami N, the World Mental Health Japan Survey Group; Barriers to mental health care in Japan: Results from the World Mental Health Japan Survey. *Psychiatry Clin Neurosci* 69: 523-533, 2015
- (84) Tanaka K, Iso N, Sagari A, Tokunaga A, Iwanaga R, Honda S, Nakane H, Ohta Y, Tanaka G; Burnout of long-term care facility employees: relationship with employees' expressed emotion toward patients. *Int J Gerontol* 9(3): 161-165, 2015
- (85) Ishikawa H, Kawakami N, Kessler R. C, the World Mental Health Japan Survey Collaborators; Lifetime and 12-month prevalence, severity and unmet need for treatment of common mental disorders in Japan: results from the final dataset of World Mental Health Japan Survey. *Epidemiol Psychiatr Sci* 1-13, 2015
- (86) 金丸由美子, 三根真理子, 中根秀之; 原爆被爆者の現状と精神健康影響－被爆者の原爆記念日前後における自尊感情の変化－. *日本社会精神医学会雑誌* 24(3): 219-227, 2015

b. 研究成果刊行物

- (1) 話し合いながら進める医療をめざして
～薬害 HIV 感染血友病等患者の医療と福祉・介護の連携や支援に関する事例集～：本文 72 頁参照
- (2) 【医療】情報収集シート／療養支援アセスメントシート（2018 年改訂）：本文 82 頁参照
- (3) 【福祉・介護】情報収集シート／療養支援アセスメントシート（2018 年改訂）：本文 83 頁参照
- (4) 療養先検討シート（2018 年改訂）：本文 84 頁参照
- (5) 薬害血友病患者の医療と福祉・介護の連携に関するハンドブック（2018 年改訂）：本文 88 頁参照
- (6) サポートファクトブック（SFB）（2016 年改訂）
- (7) サポートファクトシート（SFS）（2016 年改訂）